The CEO of a former Fortune 500 company, who is also the daughter of a U.S. senator, is under fire for jacking up the rates of a life-saving anti-allergy treatment. - From The Intercept
Amy Klobuchar, D-Minn., ranking member of the Senate Judiciary Committee’s Antitrust Subcommittee, demanded hearings on the EpiPen’s 450 percent price increase in just seven years.
One competitor, the Auvi-Q, was recalled from pharmacies last year; the Food and Drug Administration rejected another potential alternative from Teva Pharmaceuticals this spring.
In that position, she contributed to the 2003 Medicare prescription drug bill, which barred the federal insurance provider from bargaining with drug companies over prices.
While it increased regulations at Mylan’s own sites outside the U.S., it also made it more difficult for foreign drugmakers to sell their products domestically, knocking out many of Mylan’s competitors.
He has not, however, made any public statement about EpiPens since the scandal came to light, and his office did not immediately respond to a request for comment from The Intercept.